Opaleye management sells $1.06m in Eton Pharmaceuticals stock

Opaleye management sells $1.06m in Eton Pharmaceuticals stock

Stocks snap two-week win streak as AI-trade bleeds, pushing chips into bear market Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc. (NASDAQ:ETON), sold a total of 28,315 shares of the company’s common stock on July 14, 2026. The transactions amounted to a total value of $1,063,032. The shares were sold at a weighted average price of $37.5431 per share, with individual transaction prices ranging from $37.0152 to $37.9148.

The stock has since climbed to $42.33, representing a 13% gain from the sale price, as Eton shares have surged over 200% in the past year. The sales involved two distinct holdings. Opaleye Management Inc. indirectly sold 15,000 shares held by Opaleye, L.P., and an additional 13,315 shares held by a separately managed account.

Following these transactions, Opaleye, L.P. holds 2,665,000 shares, and the managed account holds 40,000 shares. Opaleye Management Inc. serves as the investment manager for Opaleye, L.P. and the portfolio manager for the managed account, and disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest. Opaleye Management Inc. is classified as a 10% owner of Eton Pharmaceuticals but does not hold a director or officer position within the company.

According to InvestingPro analysis, the stock is trading near its 52-week high of $42.65, and subscribers have access to 14 additional ProTips plus comprehensive Pro Research Reports for deeper analysis. This report is an amendment to an original filing, indicating that the reporting person is no longer subject to Section 16 requirements. In other recent news, Eton Pharmaceuticals reported its first-quarter 2026 earnings, presenting a mixed financial performance.

The company achieved a revenue of $24.3 million, which exceeded forecasts by 10.71%. However, its earnings per share (EPS) of $0.05 fell short of the anticipated $0.19, marking a 73.68% negative surprise. Additionally, H.C. Wainwright reiterated its Buy rating for Eton Pharmaceuticals, maintaining a price target of $57.00.

The firm highlighted Eton’s new supply and distribution agreement with an affiliate of Knight Therapeutics. This agreement grants Eton exclusive U.S. commercialization rights to IMPAVIDO, the only FDA-approved treatment for visceral, cutaneous, and mucosal leishmaniasis. These developments provide a multifaceted view of Eton Pharmaceuticals’ recent activities and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.